LENZ Therapeutics Reports Q3 2026 Revenue Growth Driven by Telehealth and Advertising
LENZ Therapeutics (LENZ) reported significant commercial momentum in its third quarter of 2026, with product revenue reaching $2.6 million—a 50% sequential increase. This growth was primarily fueled by the launch of national television advertising and a new telehealth channel, which accounted for over 50% of incremental prescriptions this quarter. The company's paid prescriptions rose 51% to 38,000 units, reflecting increased consumer awareness. Despite a net loss of $31 million ($0.99 per share), the company is executing a strategic reorganization to shift from traditional field sales to a consumer-led commercial model. This transition includes a projected reduction in 2027 operating expenses by more than 50% and a planned $5 million restructuring charge in Q4 2026. With $197.3 million in cash, LENZ is positioned to fund its aggressive marketing strategies and global regulatory expansions.
Tickers: $LENZ
Topics: cash position operating expense guidance restructuring revenue growth telehealth
Read the full article at Motley Fool
Part of the story UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales (7 articles)